Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  romidepsin
Find trials that include:  Any drugs shown
Results 1-16 of 16 for your search:
Start Over
Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, RM-PTCL-PI-0021, NCT01742793
Romidepsin and Lenalidomide in Treating Patients with Relapsed or Refractory Lymphoma or Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-170, NCI-2013-00005, NCT01755975
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13P.387, NCI-2013-01695, 080-38270-J94401, 13C.387, 2013-35, NCT01938833
Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140
Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAM3752, NCI-2014-00121, NCT01998035
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: 13-020, NCI-2013-01365, NCT01908777
Romidepsin and Lenalidomide in Treating Patients with Previously Untreated Peripheral T-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H04, NCI-2014-01770, RV-CL-PTCL-PI-003974, STU00097620, NCT02232516
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0183, NCI-2012-00847, NCT01590732
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11105, NCI-2012-01040, CDR0000737061, NCI-2013-01545, P9008_A10PAMDREVW01, 9008, NCT01638533
Carfilzomib with or without Romidepsin in Treating Patients with Stage IA-IVB Cutaneous T-Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H06, NCI-2012-01952, IST-CAR-532, SP0021927, STU00071042, NCT01738594
Azacitidine and Romidepsin in Treating Patients with Advanced Solid Tumors, HPV-Positive Nasopharyngeal Cancer, HPV-Positive Cervical Cancer, or Liposarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11102, NCI-2013-00930, CIR00009982, NA_00052054, NA_00052054 / CIR00007187, NCT01537744
Alisertib and Romidepsin in Treating Patients with Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0602, NCI-2013-01272, 9342, NCT01897012
Romidepsin and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Stage IB-IVB Relapsed or Refractory T-cell Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 112516, NCI-2014-01722, CC#112516, RM-CTCL-PI-0012, UCSF CC# 112516, UCSF Protocol Number 112516, NCT01902225
Radiation Therapy and Romidepsin with or without Poly ICLC in Treating Patients with Previously Treated Stage IIA-IVA Mycosis Fungoides
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S13-00686, NCI-2014-00279, i13-00686, NYU S13-00686, NCT02061449
Romidepsin, Gemcitabine Hydrochloride, Oxaliplatin, and Dexamethasone in Treating Patients with Relapsed or Refractory Aggressive Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201407160, NCI-2014-01758, 14-X091, RM-PTCL-PI-0028, NCT02181218
Start Over